Inmed pharmaceuticals (inm): notable launches of high-value rare cannabinoids

London, uk / accesswire / may 3, 2022 / inmed pharmaceuticals (inm) continues its transition from a pure-play pharma r&d firm to one also benefiting from commercial sales into the health and wellness market. product launches of high-value, rare cannabinoids into this market should provide the majority of its revenue in the near future.

INM Ratings Summary

INM Quant Ranking